SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the second of its two Phase 3 clinical trials ...

DULLES, Va., Oct. 13, 2022 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [68 Ga]FAPI-46 ...

DULLES, Va., Oct. 1, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced the successful completion of an end-of-phase 2 ...

Figure 1. Male, 46 years old, with IIP for 1 month, manifests FDG and FAPI imaging positive. (A, E, the MIP of FDG and FAPI imaging; B-C, axial FDG PET/CT, CT, and the FAPI PET/CT; The SUVmax of the ...

Figure 1. Clinical stage changed by FAPI PET/CT categorized by 18 F-FDG PET/CT in newly diagnosed breast cancer. Toronto, Ontario—A comparative analysis between FAPI and 18 F-FDG PET/CT for the ...

Five Arrows Principal Investments, Rothschild Merchant Banking‘s flagship private equity vehicle, has raised 508 million euros in the first close of its second European lower-middle market private ...

DENVER--(BUSINESS WIRE)--Ping Identity (NYSE: PING), the Intelligent Identity solution for the enterprise, showcases a continued commitment to open standards through the achievement of the ...

SOFIE Biosciences doses first patient in phase 3 study of 18F-FAPI-74 for pancreatic cancer: Dulles, Virginia Friday, February 13, 2026, 13:00 Hrs [IST] SOFIE Biosciences, an esta ...